Chemomab Therapeutics (CMMB) Net Income (2017 - 2026)
Chemomab Therapeutics' Net Income came in at $2.17 million for Q2 2026, up 5.3% from $2.06 million a year earlier and up 22.1% from the prior quarter.
Powered by 
Analysis
Chemomab Therapeutics (CMMB) Net Income (2017 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Chemomab Therapeutics reported Net Income of $7.55 million, down 36.1% year-over-year; for FY2025, it was -$9 million.
- Going back by year, Net Income was -$13.95 million in FY2024, -$24.22 million in FY2023, -$27.65 million in FY2022 and -$12.48 million in FY2021.
- The Q2 2026 figure represents the highest quarterly Net Income since Q1 2025.
- Year-over-year, Net Income increased in 1 of the last six quarters, with an average decline of 30.9%.
- The fastest year-over-year change in Net Income over five years came in Q2 2023 (growth of 8.6%), and the weakest in Q1 2024 (a decline of 55.6%).
- Business Quant data shows CMMB's Net Income at $1.77 million (Q1 2026), $1.87 million (Q4 2025) and $1.74 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | -237.00 Mn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 1.10 Bn |
| 10 | Chemomab Therapeutics | 8.56 Mn | 8.56 Mn | - | 2.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.17 Mn |
| Mar 31, 2026 | 1.77 Mn |
| Dec 31, 2025 | 1.87 Mn |
| Sep 30, 2025 | 1.74 Mn |
| Jun 30, 2025 | 2.06 Mn |
| Mar 31, 2025 | 3.32 Mn |
| Dec 31, 2024 | 2.96 Mn |
| Sep 30, 2024 | 3.48 Mn |
| Jun 30, 2024 | 3.63 Mn |
| Mar 31, 2024 | 3.87 Mn |
| Dec 31, 2023 | -3.42 Mn |
| Sep 30, 2023 | -4.08 Mn |
| Jun 30, 2023 | 7.90 Mn |
| Mar 31, 2023 | 8.71 Mn |
| Dec 31, 2022 | -8.27 Mn |
| Sep 30, 2022 | -8.08 Mn |
| Jun 30, 2022 | 7.28 Mn |
| Mar 31, 2022 | -5.10 Mn |
| Dec 31, 2021 | 19.92 Mn |
| Sep 30, 2021 | -2.97 Mn |
API Access
Chemomab Therapeutics Net Income API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income&ticker=CMMB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income", "ticker": "CMMB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income&ticker=CMMB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();